Paul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.
Paul Beresford, PhD
Advertisement
Articles by Paul Beresford, PhD
Advertisement
Latest Updated Articles
Beresford Discusses Using VeriStrat With ImmunotherapiesPublished: May 12th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5